vanoxerine has been researched along with Schizophrenia in 4 studies
vanoxerine: structure given in first source
vanoxerine : An N-alkylpiperazine that consists of piperazine bearing 2-bis(4-fluorophenyl)methoxy]ethyl and 3-phenylpropyl groups at positions 1 and 4 respectively. Potent, competitive inhibitor of dopamine uptake (Ki = 1 nM for inhibition of striatal dopamine uptake). Has > 100-fold lower affinity for the noradrenalin and 5-HT uptake carriers. Also a potent sigma ligand (IC50 = 48 nM). Centrally active following systemic administration.
Schizophrenia: A severe emotional disorder of psychotic depth characteristically marked by a retreat from reality with delusion formation, HALLUCINATIONS, emotional disharmony, and regressive behavior.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Recently, glutamate-based strategies, such as memantine add-on to antipsychotics, have been proposed for refractory symptoms of schizophrenia, e." | 7.80 | Regulation of postsynaptic plasticity genes' expression and topography by sustained dopamine perturbation and modulation by acute memantine: relevance to schizophrenia. ( Buonaguro, EF; de Bartolomeis, A; Eramo, A; Iasevoli, F; Latte, G; Marmo, F; Rossi, R; Sarappa, C; Tomasetti, C, 2014) |
| " Recently, glutamate-based strategies, such as memantine add-on to antipsychotics, have been proposed for refractory symptoms of schizophrenia, e." | 3.80 | Regulation of postsynaptic plasticity genes' expression and topography by sustained dopamine perturbation and modulation by acute memantine: relevance to schizophrenia. ( Buonaguro, EF; de Bartolomeis, A; Eramo, A; Iasevoli, F; Latte, G; Marmo, F; Rossi, R; Sarappa, C; Tomasetti, C, 2014) |
| "Schizophrenia is associated with a cerebral glutathione deficit, which may leave the brain susceptible to oxidants." | 1.32 | Low brain glutathione and ascorbic acid associated with dopamine uptake inhibition during rat's development induce long-term cognitive deficit: relevance to schizophrenia. ( Castagné, V; Cuenod, M; Do, KQ; Rougemont, M, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Górny, M | 1 |
| Wnuk, A | 1 |
| Kamińska, A | 1 |
| Kamińska, K | 1 |
| Chwatko, G | 1 |
| Bilska-Wilkosz, A | 1 |
| Iciek, M | 1 |
| Kajta, M | 1 |
| Rogóż, Z | 1 |
| Lorenc-Koci, E | 1 |
| Iasevoli, F | 1 |
| Buonaguro, EF | 1 |
| Sarappa, C | 1 |
| Marmo, F | 1 |
| Latte, G | 1 |
| Rossi, R | 1 |
| Eramo, A | 1 |
| Tomasetti, C | 1 |
| de Bartolomeis, A | 1 |
| Castagné, V | 2 |
| Cuénod, M | 2 |
| Do, KQ | 2 |
| Rougemont, M | 1 |
4 other studies available for vanoxerine and Schizophrenia